|
|
|
|
Scientists Find Heart Stem Cells
Key to the heart?Scientists have identified what they say are the heart's 'master' stem cells? Credit: Lei Bu et al., Nature 460, 113 (2009) ScienceNOW Daily News Scientists have identified a cardiac stem cell that gives...
|
|
|
Biotech company opens unit to breed pigs for human transplants
The first pig farm dedicated to breeding animals for human cell transplants has opened in Invercargill.Photo / AP Biotech entrepreneur Living Cell Technologies (LCT) has opened its first dedicated quarantine pig farm to breed...
|
|
|
Safety and viability of microencapsulated human islets transplanted into diabetic humans
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Diabetes Care, 07/02/09 Print Save in My Library Free Abstract Tuch BE et al.- Whilst allografting of encapsulated human islets is safe, efficacy of...
|
|
|
Pfizer drug slows progression of a type of pancreatic cancer
- Patients treated with Sutent for a form of pancreatic cancer survived without the disease progressing for an average of 6 months longer than patients not treated, according to a study presented today at the 11th World Congress on...
|
|
|
Another Sutent Trial Bites the Dust for Pfizer
Another late-stage trial with Pfizers Sutent has been called off.This time an evaluation of Sutent plus Folfiri versus Folfiri alone as a first-line treatment of metastatic colorectal cancer (CRC) found that a statistically significant...
|
|
|
Sutent Significantly Improved Progression-Free Survival For Patients With Advanced Pancreatic Islet Cell Tumou
Pfizer announced preliminary results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumours, also known as pancreatic neuroendocrine tumours, which is a different type...
|
|
|
Union Biometrica cytometer sorts large particles
Union Biometrica offers Copas large particle flow cytometers to analyse, sort and dispense objects that are too large (20-1,500 micron) or too delicate for traditional flow cytometers.Typical samples range from small multicellular model...
|
|
|
Isolation of tumour stem-like cells from benign tumours
Cancerous stem-like cells (CSCs) have been implicated as cancer-initiating cells in a range of malignant tumours.Diverse genetic programs regulate CSC behaviours, and CSCs from glioblastoma patients are qualitatively distinct...
|
|
|
LIVING Cell Technologies says it is ready to begin the New Zealand trial of its pig islet diabetes treatment a
_ LIVING Cell Technologies says it is ready to begin the New Zealand trial of its pig islet diabetes treatment a.
|
|
|
Sutent Significantly Improved Progression-Free Survival
Pfizer has announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer...
|
|
|
Sunitinib Significantly Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tum
my personal edition> pancreatic cancer > news E-Mail this DGDispatch to a colleague DGDispatch BARCELONA, Spain -- June 26, 2009 -- Patients with advanced pancreatic islet cell tumours experienced 2 times longer...
|
|
|
Nanobiotech Researcher Receives State Funds to Support Commercialization of diabetes treatment
Bulte and his postdoctoral fellow Dian Arifin are collaborating with the Baltimore-based company Surgivison Inc.on a project entitled Image-Guided Encapsulated Cell Therapy using Multimodal Nanoparticles. Bulte explains that the...
|
|
|
Pfizer says Sutent stopped spread of pancreatic cancer for twice as long as standard treatment
NEW YORK -- Pfizer Inc.said Thursday its cancer drug Sutent doubled the time patients with a rare form of pancreatic cancer were able to survive without the disease spreading. The late stage clinical trial compared Sutent against...
|
|
|
Pfizer says Sutent stopped spread of pancreatic cancer for twice as long as standard treatment
NEW YORK -- Pfizer Inc.said Thursday its cancer drug Sutent doubled the time patients with a rare form of pancreatic cancer were able to survive without the disease spreading. The late stage clinical trial compared Sutent against...
|
|
|
Pfizer's Sutent effective vs rare pancreatic cancer
NEW YORK - Pfizer Inc's Sutent delayed the worsening of the type of pancreatic cancer that afflicted Apple Inc Chief Executive Steve Jobs by more than five months longer than a placebo, according to data from a clinical trial.The study,...
|
|
|
Pfizer reports positive results from Phase III cancer trial
Pfizer has reported positive results from a randomized Phase III trial of Sutent in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the...
|
|
|
Pfizer Reports Positive Results For Phase-III Sutent Trial
Demonstrated median progression-free survival of 11.1 months in patients with advanced pancreatic islet cell tumors Related News Response letter is issued by FDAs Center for Drug Evaluation and Research ...GlaxoSmithKline to...
|
|
|
Research: Pfizer’s Sutent Shows Survival Benefit in Pancreatic Cancer
Patients with advanced pancreatic islet cell tumors who took Pfizers Sutent in a Phase III clinical trial lived more than twice as long without the disease pro Research: Pfizer’s Sutent Shows Survival Benefit in...
|
|
|
Tyrosine kinase inhibitor sunitinib effective for pancreatic islet cell tumors
NEW YORK (Reuters Health) - In a phase III study of patients with progressive well-differentiated pancreatic islet cell tumors, treatment with the tyrosine kinase inhibitor sunitinib significantly prolonged progression-free...
|
|
|
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumor
New Data from a Phase 3 Trial Presented KIRKLAND, QC, June 25 /CNW/ - Pfizer today announced results from a randomized Phase 3 trial of SUTENT (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known...
|
|
|
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumor
Companies mentioned in this article: Pfizer Inc NEW YORK -- (BUSINESSWIRE) -- Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors,...
|
|
|
Sutent Significantly Improved Progression-Free Survival For Patients With Advanced Pancreatic Islet Cell Tumor
NEW YORK--(BUSINESS WIRE)--Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which...
|
|
|
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumor
Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of...
|
|
|
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumor
- Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of...
|
|
|
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumor
NEW YORK-- (BUSINESS WIRE) -- Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors,...
|
